Nanobiotix SA (NBTX)
6.10
+0.05
(+0.83%)
USD |
NASDAQ |
May 03, 16:00
6.20
+0.10
(+1.64%)
After-Hours: 20:00
Nanobiotix Debt to Equity Ratio: -24.67 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | -24.67 |
| June 30, 2023 | -0.9064 |
| December 31, 2022 | -1.761 |
| June 30, 2022 | 21.85 |
| December 31, 2021 | 1.474 |
| June 30, 2021 | 1.090 |
| December 31, 2020 | 0.6072 |
| June 30, 2020 | -2.040 |
| December 31, 2019 | -19.97 |
| June 30, 2019 | 1.787 |
| December 31, 2018 | 1.441 |
| June 30, 2018 | 0.1246 |
| Date | Value |
|---|---|
| December 31, 2017 | 0.1028 |
| June 30, 2017 | 0.1671 |
| December 31, 2016 | 0.312 |
| June 30, 2016 | 0.149 |
| December 31, 2015 | 0.2947 |
| June 30, 2015 | 0.1958 |
| December 31, 2014 | 0.0766 |
| June 30, 2014 | 0.0519 |
| December 31, 2013 | 0.3477 |
| June 30, 2013 | |
| December 31, 2012 | 0.1339 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-24.67
Minimum
Dec 2023
21.85
Maximum
Jun 2022
-2.254
Average
-0.1496
Median
Debt to Equity Ratio Benchmarks
| DBV Technologies SA | -- |
| Cellectis SA | 0.3968 |
| PHAXIAM Therapeutics SA (DELISTED) | -- |
| Genfit SA | 0.9462 |
| Innate Pharma SA | 0.7525 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 103.79M |
| Total Liabilities (Quarterly) | 105.83M |
| Shareholders Equity (Quarterly) | -2.038M |
| Current Ratio | 1.751 |
| Net Debt Paydown Yield | -0.91% |